कंपनी का अवलोकन
biote Corp. operates primarily within the practice-building sector of the healthcare industry, specifically focusing on the hormone optimization space. The company trains physicians and nurse practitioners to utilize bioidentical hormone replacement pellet therapy for treating hormonal imbalances in both men and women. This specialized business model positions biote Corp. as a key player in the medical care facilities industry, which is characterized by service-oriented revenue generation rather than product manufacturing. The entity employs 223 individuals and maintains a market capitalization of $56.27M, reflecting its status as a small-cap entity within the broader healthcare ecosystem. Its annual revenue stands at $192.22M, a figure that, while substantial for a practice-building firm, indicates a mid-sized operational scale relative to large pharmaceutical or hospital corporations. The market cap suggests that the market values the company's intangible assets and service delivery model at a level consistent with its niche positioning in hormone optimization. Revenue of $192.22M demonstrates that the company has achieved significant traction in its specific vertical, yet the market cap implies that investors are pricing the stock with caution regarding future scalability or competitive pressures in the hormone therapy market.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $192.22M, generating a net income of $27.05M and an EBITDA of $37.54M. The significant gap between the revenue of $192.22M and the net income of $27.05M reveals a cost structure where operating expenses, including cost of goods sold, administrative costs, and potentially high customer acquisition costs, absorb approximately 86% of total revenue. Free cash flow stands at $13.27M, which indicates that the company generates positive cash from operations after capital expenditures, providing a degree of financial flexibility for working capital management or potential strategic investments. The company maintains a gross margin of 71.5%, suggesting a high-margin business model typical of service-based or low-cost-of-goods businesses where value is derived from expertise and training. Operating margins are reported at 9.4%, indicating that after covering operating expenses, the company retains a moderate portion of revenue as operating profit, while the profit margin of 14.1% shows the final profitability after all expenses including interest and taxes. Regarding balance sheet leverage, the company holds $24.12M in cash against $109.92M in debt, and the debt-to-equity ratio is listed as N/A, which implies that the company may have minimal equity on the books or that the leverage is viewed differently in its capital structure analysis, potentially indicating a leveraged position relative to its cash reserves. The current ratio is 1.22, which signifies that the company has sufficient current assets to cover its short-term liabilities with a ratio above one, indicating reasonable but not excessive short-term liquidity. Return on equity is listed as N/A, while return on assets stands at 19.1%, a metric that reveals how efficiently management utilizes the company's total asset base to generate earnings.
मूल्यांकन आकलन
The trailing P/E ratio is 2.04, while the forward P/E is 2.65. The difference between these two metrics implies that the market expects earnings growth in the future that is higher than the historical earnings, as the forward multiple is higher than the trailing multiple. The price-to-book ratio is -0.79, which indicates a negative relationship where the market capitalization is less than the book value, or potentially that the book value is negative due to accumulated deficits or accounting adjustments, suggesting the market does not value the company at a premium over its book value. The price-to-sales ratio is 0.29, and the EV/EBITDA is 3.74. These alternative valuation metrics suggest that the stock is trading at a very low multiple of its sales and earnings, indicating a potential undervaluation or significant market skepticism regarding future cash flows relative to its size. The 52-week high is $4.75 and the 52-week low is $1.27. To determine the current price position relative to this range, one must analyze the implied current price based on the market cap and share count, though without the exact share count, we can infer the price range volatility; however, strictly adhering to the facts, the stock has exhibited significant volatility within a range of $1.27 to $4.75 over the past year. The beta value is 1.29, which explains that the stock's price volatility is higher than the broader market, moving 29% more than the market average in response to market movements.
Growth & Income
Revenue growth year-over-year is -6.9%, and earnings growth year-over-year is -36.7%. The fact that earnings growth is declining at a much faster rate (-36.7%) than revenue (-6.9%) implies that the company's profitability is under pressure, potentially due to rising costs, margin compression, or a decline in the efficiency of its practice-building model. The dividend yield is N/A, and the payout ratio is 0.0%, indicating that the company does not currently pay dividends to shareholders. For non-dividend payers like biote Corp., this structure explains that the company reinvests its earnings into growth initiatives, such as expanding its training programs or acquiring new practices, rather than distributing cash to investors. The overall growth and income profile for biote Corp. is characterized by negative growth in both revenue and earnings, coupled with a lack of dividend distribution, which presents a specific risk-return dynamic for investors analyzing the financial data of the company.